An analysis of early insulin glargine added to metformin with or without sulfonylurea: Impact on glycaemic control and hypoglycaemia

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 814-822

  Fonseca, V ^a   Gill, J ^b   Zhou, R ^c   Leahy, J ^d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

^c Medpace ^*  (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Basal insulin therapy; Insulin glargine; Metformin; Oral antidiabetic drugs; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN;

EID: 79960758089     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01412.x     Document Type: Article

References (15)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. Prospective Diabetes Study 61. Diabetes Care 2002; 25: 1410-1417.
3. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18-S24.
4. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006; 32: 9S-18S.
5. Gerstein HC, Yale J-F, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas: the Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-742.
6. Riddle MC, Rosenstock J, Gerich J. Insulin glargine 4002 study investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
7. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006; 38: 172-177.
8. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
9. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
10. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.
11. Yki-Jarvinen H, Juurinen L, Alvarsson M et al. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.
12. Blickle J-F, Hancu N, Piletic M et al. Insulin glargine provides greater improvements in glycaemic control vs intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1C levels; the TULIP study. Diabetes Obes Metab 2009; 11: 379-386.
13. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451.
14. Meneghini LF, Taylor L, Schwartz S. Improved glycemic control with insulin glargine vs pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes. Endocr Pract 2010; 16: 588-599.
15. Huedo-Medina T, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Paper 2006; 19. Available from URL:. Accessed 8 February 2011.